Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKOVAZ vs BACTROBAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.
Treatment of clinically important hypotension occurring in the setting of anesthesia
Impetigo due to Staphylococcus aureus and Streptococcus pyogenes,Mupirocin-sensitive infections
5 mg intravenously once daily.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Hepatic metabolism via oxidative deamination and demethylation; primarily metabolized by CYP2D6; some metabolites are active.
Minimal systemic absorption; rapidly metabolized to monic acid (inactive) in skin and systemically.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
85% bound to albumin and alpha-1-acid glycoprotein.
95% bound, primarily to albumin
Vd: 1.5-2.0 L/kg, indicating extensive tissue distribution.
0.15-0.3 L/kg, indicating distribution primarily into extracellular fluid
Oral: 75% (first-pass metabolism minimal).
Topical: Negligible systemic absorption (<0.05% after topical application to intact skin; slightly higher (up to 1%) on abraded skin; intranasal: <0.1%
Not required as AKOVAZ is not renally excreted.
No dosage adjustment necessary for topical application. For intranasal use, no adjustment required. Systemic absorption is minimal.
No dose adjustment needed based on Child-Pugh classification.
No dosage adjustment necessary for topical or intranasal use. Systemic absorption is minimal.
0.1 mg/kg intravenously once daily, maximum 5 mg.
Children 3 months and older: Same as adult dosing. Topical: apply 2% ointment/cream three times daily for 5 to 14 days. Intranasal: apply 0.5 g of 2% ointment to each nostril twice daily for 5 days.
No specific dose adjustment required; use caution due to potential age-related decreased renal function.
No specific adjustments required. Use same dosing as adults. Caution in patients with renal impairment due to potential accumulation of polyethylene glycol vehicle with extensive use on open wounds or burns.
None
None.
Hypertension: May cause severe hypertension, including hypertensive crisis, especially with concurrent MAOIs or other vasopressors.,Arrhythmias: May induce ventricular arrhythmias, especially in patients with underlying cardiac disease.,Risk of stroke: Hypertensive effects may increase risk of intracranial hemorrhage.,Tachyphylaxis: Repeated use may lead to decreased response.,Extravasation: Risk of tissue necrosis if extravasation occurs.,Use caution in patients with hyperthyroidism, pheochromocytoma, or diabetes.
Severe allergic reactions including anaphylaxis and angioedema; potential for superinfection with prolonged use; not for intranasal use except specific formulations.
Hypersensitivity to ephedrine or other sympathomimetics,Concurrent use with MAOIs or within 14 days after discontinuation,Angle-closure glaucoma,Severe hypertension or cardiovascular disease
Known hypersensitivity to mupirocin or any component of the formulation.
No known food interactions. This drug is administered intravenously, so dietary restrictions are not applicable. However, oral intake should not interfere with therapy.
No known food interactions. The drug is applied topically; oral intake does not affect its action.
Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. In second and third trimesters, use may cause fetal tachycardia, reduced uteroplacental blood flow, and potential for neonatal withdrawal or toxicity. Risk of maternal hypertension and decreased uterine perfusion outweighs benefits unless clearly indicated.
No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.
Ephedrine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.5-3.0. Peak milk concentration occurs 1-2 hours after dose. Potential for infant stimulation, irritability, and sleep disturbances. Use with caution; monitor infant for adverse effects. Avoid in lactation if possible or use lowest effective dose for shortest duration.
Unknown if excreted in human milk; caution advised. M/P ratio not established.
Pharmacokinetic changes in pregnancy (increased plasma volume, altered binding proteins) may reduce peak concentrations of ephedrine. However, no specific dose adjustment recommendations are established for Akovaz in pregnancy. Use the lowest effective dose to achieve desired effect (typically 5-10 mg IV for hypotension). Monitor clinical response closely; dose titration may be needed due to altered sensitivity of adrenergic receptors in pregnancy. Avoid prolonged use.
No dose adjustments recommended; systemic absorption is minimal.
AKOVAZ (ceftolozane/tazobactam) is a cephalosporin/beta-lactamase inhibitor combination used primarily for hospital-acquired pneumonia and complicated urinary tract infections. Monitor renal function closely; dose adjustment required for Cr Cl < 50 m L/min. Administer intravenously over 1 hour. Observe for hypersensitivity reactions, including anaphylaxis, particularly in penicillin-allergic patients. Consider cross-reactivity with other beta-lactams. Collect cultures before initiation.
BACTROBAN (mupirocin) is a topical antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. It is contraindicated for use on burns or large open wounds due to risk of polyethylene glycol absorption. For impetigo, apply to affected area three times daily for 5-10 days. Not effective against fungal, viral, or anaerobic infections. Monitor for local irritation; discontinue if severe. Use intranasal formulation (BACTROBAN Nasal) for MRSA decolonization.
This medication is given intravenously to treat serious bacterial infections.,Report any signs of allergic reaction immediately: rash, itching, difficulty breathing, swelling of face or throat.,Diarrhea may occur; contact your provider if it is severe, watery, or bloody.,Do not skip doses; complete the full course of treatment even if you feel better.,Tell your healthcare provider about all medications, especially blood thinners (e.g., warfarin) and other antibiotics.,Kidney function will be monitored with blood tests; drink adequate fluids unless told otherwise.
Apply a small amount of ointment to the affected area 3 times daily, or as directed.,Wash hands before and after application to prevent spreading infection.,Do not use on large areas of broken skin or deep wounds without medical advice.,Avoid contact with eyes and mucous membranes.,Complete the full course of treatment even if symptoms improve.,Stop use and contact doctor if rash or irritation occurs.,Do not share this medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKOVAZ vs BACTROBAN, answered by our medical review team.
AKOVAZ is a Topical Antibiotic that works by Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.. BACTROBAN is a Topical Antibiotic that works by Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKOVAZ and BACTROBAN depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKOVAZ is: 5 mg intravenously once daily.. The standard adult dose of BACTROBAN is: Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKOVAZ and BACTROBAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKOVAZ is classified as Category C. Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. I. BACTROBAN is classified as Category C. No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.